Dissecting the mode of action of various HIV-inhibitor classes in a stable cellular system

Archives of Virology

Volumn 143, Issue 11, 1998, Pages 2109-2131

  Klimkait, T ^a,b   Stauffer, F ^a   Lupo, E ^a   Sonderegger Rubli, C ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL LINE; FUSION INDUCED GENE STIMULATION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; LYMPHOCYTE; MEMBRANE FUSION; PLASMID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INFECTION;

ANTI-HIV AGENTS; CELL LINE; COCULTURE TECHNIQUES; DRUG RESISTANCE, MICROBIAL; GENES, REPORTER; HELA CELLS; HIV LONG TERMINAL REPEAT; HIV-1; HIV-2; HUMANS; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSFECTION; VIRUS ACTIVATION;

FICUS (ANGIOSPERM); HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0031742023     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007050050447     Document Type: Article

References (41)

1. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and non human cells transfected with an infectious molecular clone. J Virol 59: 1 157-1 161
2. Akrigg A, Wilkinson GW, Angliss S, Greenaway PJ (1991) HIV-1 indicator cell lines. AIDS 5: 153-158
3. Alteri E, Bold G, Cozens R, Faessler A, Klimkait T, Lang M, Lazdins JK, Poncioni B, Roesel J, Schneider P, Walker M, Woods-Cook K (1993) CGP53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrob Agents Chemother 37: 2 087-2 092
4. Berkhout B, Gatignol A, Silver J, Jeang KT (1990) Efficient trans-activation by the HIV-2 Tat protein requires a duplicated TAR RNA structure. Nucleic Acids Res 18: 1 839-1 846
5. Biegale BJ, Geballe AP (1991) Sequence requirements for activation of the HIV-1 LTR by human cytomegalovirus. Virology 183: 381-385
6. Blochinger K, Diggelmann H (1984) Hygromycin B phosphotransferase as a selectable marker for DNA transfer experiments with higher eucaryotic cells. Mol Cell Biol 4: 2 929-2 931
7. Bonnerot C, Rocancourt D, Briand P, Grimber G, Nicolas JF (1987) A beta-galactosidase hybrid protein targeted to nuclei as a marker for developmental studies. Proc Natl Acad Sci USA 84: 6 795-6 799
8. Bruder JT, Heidecker G, Tan TH, Weske JC, Derse D, Rapp UR (1993) Oncogene activation of HIV-LTR-driven expression via the NF-kappa B binding sites. Nucleic Acids Res 21: 5 229-5 234
9. Calnan BJ, Tidor B, Biancalana S, Hudson D, Frankel AD (1991) Arginine-mediated RNA recognition: the arginine fork. Science 252: 1 167-1 171
10. Chesebro B, Wehrly K (1988) Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol 62: 3 779-3 788
11. Ciminale V, Felber BK, Campbell M, Pavlakis GN (1990) A bioassay for HIV-1 based on Env-CD4 interaction. AIDS Res Hum Retroviruses 6: 1 281-1 287
12. Clavel F, Chameau P (1994) Fusion from without directed be human immunodeficiency virus particles. J Virol 68: 1 179-1 185
13. Daly TJ, Rennert P, Lynch P, Barry JK, Dundas M, Rusche JR, Doten RC, Auer M, Farrington GK (1993) Perturbation of the carboxy terminus of HIV-1 Rev affects multimerization on the Rev responsive element. Biochemistry 32: 8 945-8 954
14. Emerman M, Guyader M, Montagnier L, Baltimore D, Muesing MA (1987) The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1. EMBO J 6: 3 755-3 760
15. Felser JM, Klimkait T, Silver J (1989) A syncytia assay for human immunodeficiency virus type 1 (HTV-1) envelope protein and its use in studying HIV-1 mutations. Virology 170: 566-570
16. Gatignol A, Kumar A, Rabson A, Jeang KT (1989) Identification of cellular proteins that bind to the human immunodeficiency virus type 1 trans-activation-responsive TAR element RNA. Proc Natl Acad Sci USA 86: 7 828-7 832
17. Gazdar AF, Carney DN, Bunn PA, Russell EK, Jaffe ES, Schechter GP, Guccion JG (1980) Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood 55: 409-417
18. Gentz R, Chen C-H, Rosen CA (1989) Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: trans-activation requires mRNA synthesis. Proc Natl Acad Sci USA 86: 821-824
19. Graham FL, van der Eb AJ (1973) Transformation of rat cells by DNA of human adenovirus 5. Virology 54: 536-539
20. Hamy F, Felder ER, Heizmann G, Lazdins J, Aboul-ela F, Varani G, Karn J, Klimkait T (1997) An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci USA 94: 3 548-3 553
21. Hamy F, Brondani V, Floersheimer A, Stark W, Blommers MJJ, Klimkait T (1998) A new class of HIV-1 Tat antagonist acting through Tat/TAR inhibition. Biochemistry 37: 5 086-5 095
22. Hsu M-C, Schutt AD, Holly M, Slice LW, Sherman MI, Richman DD, Potash MJ, Volsky DJ (1991) Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science 254: 1 799-1 802
23. Ish-Horowicz D, Burke JF (1981) Rapid and efficient cosmid cloning. Nucleic Acids Res 9: 2 989-2 998
24. Keller R, Peden K, Paulous S, Montagnier L, Cordonnier A (1993) Amino acid changes in the fourth conserved region of human immunodeficiency virus type 2 strain HIV-2ROD envelope glycoprotein modulate fusion. J Virol 67: 6 253-6 258
25. Kimpton J, Emerman M (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 66: 2 232-2 239
26. Klotman ME, Kim S, Buchbinder A, DeRossi A, Baltimore D, Wong-Staal F (1991) Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc Natl Acad Sci USA 88: 5 011-5 015
27. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685
28. Lim K, Chae CB (1989) A simple assay for DNA transfection by incubation of the cells in culture dishes with substrates for beta-galactosidase. Biotechniques 7: 576-579
29. McDougal JS, Cort SP, Kennedy MS, Cabradilla CD, Feorino PM, Francis DP, Hicks D, Kalyanaraman VS, Martin LS (1985) Immunoassay for the detection and quantification of infectious human retrovirus, lymphadenopathy-associated virus (LAV). J Immunol Methods 76: 171-183
30. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R (1986) The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47: 333-348
31. Maio JJ, Brown FL (1988) Regulation of expression driven by human immunodeficiency virus type 1 and human T-cell leukemia virus type 1 long terminal repeats in pluripotent human embryonic cells. J Virol 62: 1 398-1 407
32. Nara PL, Hatch WC, Dunlop NM, Robey WG, Fischinger PJ (1987) Simple, rapid quantitative, syncytium forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses 3: 283-302
33. O'Brien WA, Sumner-Smith M, Mao SH, Sadeghi S, Zhao JQ, Chen IS (1996) Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp 120 V3 interactions. J Virol 70: 2 825-2 831
34. Rattner A, Korner M, Walker MD, Citri Y (1993) NF-kappa B activates the HIV promoter in neurons. EMBO J 12: 4 261-4 267
35. Rocancourt D, Bonnerot C, Jouin H, Emerman M, Nicolas JF (1990) Activation of a betagalactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J Virol 64: 2 660-2 668
36. Smith MR, and Greene WC (1989) The same 50-kDa cellular protein binds to the negative regulatory elements of the interleukin 2 receptor alpha-chain gene and the human immunodeficiency virus type 1 long terminal repeat. Proc Natl Acad Sci USA 86: 8 526-30
37. gag processing of inhibitor-resistant HIV-1 protease mutants correspond to reduced viral growth. (submitted)
38. Willey RL, Klimkait T, Frucht DM, Bonifacino JS, Martin MA (1991) Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing. Virology 184: 319-329
39. Witvrouw M, Pauwels R, Vandamme A-M, Schols D, Reymen D, Yamamoto N, Desmyter J, DeClerq E (1992) Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3 335. Antimicrob Agents Chemother 36: 2 628-2 633
40. Wyatt JR, Vickers TA, Robertson JL, Buckheit RW, Klimkait T, DeBaets E, Davis PW, Rayner B, Imbach JL, Ecker DJ (1994) Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci USA 91: 1 356-1 360
41. Zhou Y, Chang CK, Qian G, Chandran B, Wood C (1994) Trans-activation of the HIV promoter by a cDNA and its genomic clones of human herpesvirus-6. Virology 199: 311-22